Intravitreal AAVCAGsCD59

BIOLOGICAL2 trials

Sponsors

Janssen Research & Development, LLC, Hemera Biosciences

Conditions

Dry Age-related Macular DegenerationGene TherapyGeographic AtrophyIntravitreal InjectionWet Age-related Macular Degeneration

Phase 1

AAVCAGsCD59 for the Treatment of Wet AMD

CompletedNCT03585556

Janssen Research & Development, LLCWet Age-related Macular Degeneration

Start: 2018-09-13End: 2022-01-18Updated: 2025-03-30

Phase 2

Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)

WithdrawnNCT04358471

Hemera BiosciencesDry Age-related Macular Degeneration, Gene Therapy, Geographic Atrophy +1

Start: 2021-07-31End: 2023-09-01Updated: 2021-05-10